MDR1 Ala893 Polymorphism Is Associated with Inflammatory Bowel Disease

Ameyaw, 2001, MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity, Pharmacogenetics, 11, 217, 10.1097/00008571-200104000-00005 Bernal, 2003, Frequency distribution of C3435T mutation in exon 26 of the MDR1 gene in a Spanish population, Ther Drug Monit, 25, 107, 10.1097/00007691-200302000-00016 Binder, 1998, Genetic epidemiology in inflammatory bowel disease, Dig Dis, 16, 351, 10.1159/000016891 Bonen, 2003, Crohn’s disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan, Gastroenterology, 124, 140, 10.1053/gast.2003.50019 Calado, 2002, Influence of functional MDR1 gene polymorphisms on P-glycoprotein activity in CD34+ hematopoietic stem cells, Haematologica, 87, 564 Cascorbi, 2001, Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects, Clin Pharmacol Ther, 69, 169, 10.1067/mcp.2001.114164 Chamaillard, 2003, Gene-environment interaction modulated by allelic heterogeneity in inflammatory diseases, Proc Natl Acad Sci USA, 100, 3455, 10.1073/pnas.0530276100 Chambers, 1993, Identification of specific sites in human P-glycoprotein phosphorylated by protein kinase C, J Biol Chem, 268, 4592, 10.1016/S0021-9258(18)53436-0 Cho, 1998, Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: evidence for epistasis between 1p and IBD1, Proc Natl Acad Sci USA, 95, 7502, 10.1073/pnas.95.13.7502 Choi, 1988, An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene, Cell, 53, 519, 10.1016/0092-8674(88)90568-5 Duerr, 2000, High-density genome scan in Crohn disease shows confirmed linkage to chromosome 14q11-12, Am J Hum Genet, 66, 1857, 10.1086/302947 Duffy, 1997, Sib-pair: a program for non-parametric linkage/association analysis, Am J Hum Genet, 61, A197 Farrell, 2000, High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy, Gastroenterology, 118, 279, 10.1016/S0016-5085(00)70210-1 Furuno, 2002, Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson’s disease, Pharmacogenetics, 12, 529, 10.1097/00008571-200210000-00004 Germann, 1996, Characterization of phosphorylation-defective mutants of human P-glycoprotein expressed in mammalian cells, J Biol Chem, 271, 1708, 10.1074/jbc.271.3.1708 Girardin, 2003, Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection, J Biol Chem, 278, 8869, 10.1074/jbc.C200651200 Hampe, 1999, A genomewide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort, Am J Hum Genet, 64, 808, 10.1086/302294 Hardy, 1995, Protein kinase C-mediated phosphorylation of the human multidrug resistance P-glycoprotein regulates cell volume-activated chloride channels, Embo J, 14, 68, 10.1002/j.1460-2075.1995.tb06976.x Higgins, 1992, Is the multidrug transporter a flippase?, Trends Biochem Sci, 17, 18, 10.1016/0968-0004(92)90419-A Hitzl, 2001, The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells, Pharmacogenetics, 11, 293, 10.1097/00008571-200106000-00003 Hoffmeyer, 2000, Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo, Proc Natl Acad Sci USA, 97, 3473, 10.1073/pnas.97.7.3473 Hugot, 2001, Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease, Nature, 411, 599, 10.1038/35079107 Hugot, 1996, Mapping of a susceptibility locus for Crohn’s disease on chromosome 16, Nature, 379, 821, 10.1038/379821a0 Inohara, 2003, Host recognition of bacterial muramyl dipeptide mediated through NOD2: implications for Crohn’s disease, J Biol Chem, 278, 5509, 10.1074/jbc.C200673200 Johne, 2002, Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene, Clin Pharmacol Ther, 72, 584, 10.1067/mcp.2002.129196 Jones, 1998, A new structural model for P-glycoprotein, J Membr Biol, 166, 133, 10.1007/s002329900455 Kim, 2001, Identification of functionally variant MDR1 alleles among European Americans and African Americans, Clin Pharmacol Ther, 70, 189, 10.1067/mcp.2001.117412 Kong, 1997, Allele-sharing models: LOD scores and accurate linkage tests, Am J Hum Genet, 61, 1179, 10.1086/301592 Kruglyak, 1996, Parametric and nonparametric linkage analysis: a unified multipoint approach, Am J Hum Genet, 58, 1347 Kruglyak, 2001, Variation is the spice of life, Nat Genet, 27, 234, 10.1038/85776 Lown, 1997, Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine, Clin Pharmacol Ther, 62, 248, 10.1016/S0009-9236(97)90027-8 Ma, 1999, A genome-wide search identifies potential new susceptibility loci for Crohn’s disease, Inflamm Bowel Dis, 5, 271, 10.1097/00054725-199911000-00005 Markianos, 2001, Efficient multipoint linkage analysis through reduction of inheritance space, Am J Hum Genet, 68, 963, 10.1086/319507 Martin, 2000, A test for linkage and association in general pedigrees: the pedigree disequilibrium test, Am J Hum Genet, 67, 146, 10.1086/302957 Nakamura, 2002, Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects, Clin Pharmacol Ther, 71, 297, 10.1067/mcp.2002.122055 Ogura, 2001, A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease, Nature, 411, 603, 10.1038/35079114 Orholm, 1991, Familial occurrence of inflammatory bowel disease, N Engl J Med, 324, 84, 10.1056/NEJM199101103240203 Paavola-Sakki, 2003, Genome-wide search in Finnish families with inflammatory bowel disease provides evidence for novel susceptibility loci, Eur J Hum Genet, 11, 112, 10.1038/sj.ejhg.5200936 Panwala, 1998, A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis, J Immunol, 161, 5733 Peeters, 1996, Familial aggregation in Crohn’s disease: increased age-adjusted risk and concordance in clinical characteristics, Gastroenterology, 111, 597, 10.1053/gast.1996.v111.pm8780562 Podolsky, 2002, Inflammatory bowel disease, N Engl J Med, 347, 417, 10.1056/NEJMra020831 Rioux, 2000, Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci, Am J Hum Genet, 66, 1863, 10.1086/302913 Satsangi, 1996, Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12, Nat Genet, 14, 199, 10.1038/ng1096-199 Schinkel, 1997, The physiological function of drug-transporting P-glycoproteins, Semin Cancer Biol, 8, 161, 10.1006/scbi.1997.0068 Schinkel, 1997, Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins, Proc Natl Acad Sci USA, 94, 4028, 10.1073/pnas.94.8.4028 Schinkel, 1996, P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs, J Clin Invest, 97, 2517, 10.1172/JCI118699 Schinkel, 1995, Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A, J Clin Invest, 96, 1698, 10.1172/JCI118214 Schwab, 2003, Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis, Gastroenterology, 124, 26, 10.1053/gast.2003.50010 Siddiqui, 2003, Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1, N Engl J Med, 348, 1442, 10.1056/NEJMoa021986 Siegmund, 2002, The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol, Clin Pharmacol Ther, 72, 572, 10.1067/mcp.2002.127739 Sparreboom, 1997, Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine, Proc Natl Acad Sci USA, 94, 2031, 10.1073/pnas.94.5.2031 Subhani, 1998, Concordance rates of twins and siblings in inflammatory bowel disease, Gut Suppl, 42, A40 Thompson, 1996, Genetics versus environment in inflammatory bowel disease: results of a British twin study, BMJ, 312, 95, 10.1136/bmj.312.7023.95 Tysk, 1988, Ulcerative colitis and Crohn’s disease in an unselected population of monozygotic and dizygotic twins: a study of heritability and the influence of smoking, Gut, 29, 990, 10.1136/gut.29.7.990 Ueda, 1987, Expression of a full-length cDNA for the human “MDR1” gene confers resistance to colchicine, doxorubicin, and vinblastine, Proc Natl Acad Sci USA, 84, 3004, 10.1073/pnas.84.9.3004 van Helvoort, 1996, MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine, Cell, 87, 507, 10.1016/S0092-8674(00)81370-7 Verstuyft, 2003, Digoxin pharmacokinetics and MDR1 genetic polymorphisms, Eur J Clin Pharmacol, 58, 809, 10.1007/s00228-003-0567-5 Weir, 1996 Williams, 2002, Using a genome-wide scan and meta-analysis to identify a novel IBD locus and confirm previously identified IBD loci, Inflamm Bowel Dis, 8, 375, 10.1097/00054725-200211000-00001 Yamauchi, 2002, Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene, Transplantation, 74, 571, 10.1097/00007890-200208270-00024